Literature DB >> 12907007

Decreased mortality of ischaemic heart disease among carriers of haemophilia.

A Srámek1, M Kriek, F R Rosendaal.   

Abstract

BACKGROUND: Coagulation plays an important part in ischaemic cardiovascular disease. Results of studies have shown that extremes in hypocoagulability protect against ischaemic cardiovascular disease. We have investigated overall mortality and death from cardiovascular causes in carriers of haemophilia, who in most cases have mildly decreased coagulability without clinical signs.
METHODS: We followed-up a cohort of 1012 mothers of all known people with haemophilia in the Netherlands from birth to death, or the end-of-study date (41984 person years of follow-up). We obtained vital status and causes of death, if deceased, and compared overall and cause-specific mortality in our cohort with that in the general Dutch female population adjusted for age and calendar period by calculating the standardised mortality ratio (SMR).
FINDINGS: Overall mortality was reduced by 22% (261 observed deaths, 333.74 expected; SMR 0.78 [95% CI 0.69-0.88]). Deaths from ischaemic heart disease were reduced by 36% (39 observed deaths, 60.53 expected; SMR 0.64 [0.47-0.88]). We did not note decreased mortality for cerebral stroke (ischaemic and haemorrhagic combined) (28 observed deaths, 36.82 expected; SMR 0.76 [0.53-1.10]). A separate analysis of these two types of stroke was not possible. Women in our cohort had an increased risk of death from extracranial haemorrhage (5 observed deaths, 0.18 expected; SMR 27.78 [8.49-58.18]); however, the number of deaths from this cause was much lower than that for ischaemic heart disease.
CONCLUSION: The results show that a mild decrease in coagulability has a protective effect against fatal ischaemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907007     DOI: 10.1016/s0140-6736(03)14021-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  24 in total

Review 1.  Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Authors:  Thomas J Povsic; Bruce A Sullenger; Steven L Zelenkofske; Christopher P Rusconi; Richard C Becker
Journal:  J Cardiovasc Transl Res       Date:  2010-11-16       Impact factor: 4.132

Review 2.  The hemostatic balance revisited through the lessons of mankind evolution.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2008-02-19       Impact factor: 3.397

3.  Factor IX and deep vein thrombosis.

Authors:  Gordon Lowe
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

Review 4.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

5.  Coronary atherosclerosis and cardiovascular mortality in hemophilia.

Authors:  C J Foley; L Nichols; K Jeong; C G Moore; M V Ragni
Journal:  J Thromb Haemost       Date:  2009-10-26       Impact factor: 5.824

Review 6.  Can haemostatic factors predict atherothrombosis?

Authors:  Gordon Lowe
Journal:  Intern Emerg Med       Date:  2011-02-15       Impact factor: 3.397

Review 7.  Myocardial infarction, other arterial thrombosis and invasive coronary procedures, in hemaophilia B: a critical evaluation of reported cases.

Authors:  A Girolami; M L Randi; E Ruzzon; E Zanon; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

8.  Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture.

Authors:  Zhi Xu; Francis J Castellino; Victoria A Ploplis
Journal:  Blood       Date:  2009-12-15       Impact factor: 22.113

Review 9.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

10.  Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.

Authors:  Reut Shnerb Ganor; Dror Harats; Ginette Schiby; David Gailani; Hanna Levkovitz; Camila Avivi; Ilia Tamarin; Aviv Shaish; Ophira Salomon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-21       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.